Post-Operative pain after a surgical procedure is commonplace and often very severe. Approximately 80% of patients experience pain after surgery with 86% having moderate, severe or extremely severe pain. Effective pain relief can have a significant effect on a patient’s recovery and ultimate discharge from the hospital. Unfortunately, it is estimated that more than 40% experience Post-Operative Nausea and Vomiting (PONV). Often patient satisfaction is closely tied to avoidance of nausea and vomiting after surgery. In fact, nausea and vomiting rank ahead of many other possible complications such as pain, heart attack or strokes. The post-operative market has been growing steadily with an expectation to exceed $6 billion by 2014. It has been reported that the efficacy of currently available therapies in the post-operative setting are efficacious but that the side effects are dose limiting because the strongest analgesics are associated with Post-Operative Nausea and Vomiting (PONV). Strong opioids such as hydrocodone, oxycodone and morphine drive most of the market share in the post-operative setting, but they, too, are associated with high incidence of Post-Operative Nausea and Vomiting (PONV).
Charleston Laboratories, Inc is dedicated to developing novel opioid analgesics without Post-Operative Nausea and Vomiting (PONV).